Soligenix (SNGX) Competitors $2.75 -0.17 (-5.82%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$2.78 +0.03 (+1.09%) As of 09/15/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. FGEN, TPST, VRCA, LTRN, PEPG, NBRV, RNXT, ATHE, AADI, and ANVSShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Aadi Bioscience (AADI), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Annovis Bio FibroGen (NASDAQ:FGEN) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Do analysts recommend FGEN or SNGX? FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 263.18%. Soligenix has a consensus price target of $6.00, suggesting a potential upside of 118.18%. Given FibroGen's higher probable upside, research analysts plainly believe FibroGen is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, FGEN or SNGX? Soligenix has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M1.61-$47.58M-$0.38-31.16Soligenix$120K98.31-$8.27M-$3.80-0.72 Is FGEN or SNGX more profitable? Soligenix has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. FibroGen's return on equity of 0.00% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-3.86% N/A -27.34% Soligenix N/A -274.76%-129.20% Do insiders and institutionals believe in FGEN or SNGX? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 2.0% of FibroGen shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, FGEN or SNGX? FibroGen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Does the media refer more to FGEN or SNGX? In the previous week, FibroGen had 2 more articles in the media than Soligenix. MarketBeat recorded 4 mentions for FibroGen and 2 mentions for Soligenix. Soligenix's average media sentiment score of 1.45 beat FibroGen's score of 0.11 indicating that Soligenix is being referred to more favorably in the news media. Company Overall Sentiment FibroGen Neutral Soligenix Positive SummarySoligenix beats FibroGen on 8 of the 15 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.51M$3.15B$5.80B$10.17BDividend YieldN/A2.32%5.73%4.61%P/E Ratio-0.7221.2474.8626.39Price / Sales98.31472.01544.60190.76Price / CashN/A44.4425.8129.91Price / Book1.689.6413.256.28Net Income-$8.27M-$53.20M$3.29B$270.38M7 Day Performance2.61%0.07%0.07%1.89%1 Month Performance-1.08%4.27%4.59%6.01%1 Year Performance-21.65%9.62%72.95%25.26% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix2.902 of 5 stars$2.75-5.8%$6.00+118.2%-23.8%$12.51M$120K-0.7220Positive NewsShort Interest ↓Gap DownFGENFibroGen4.4676 of 5 stars$11.16-7.8%$43.00+285.3%+0.8%$48.93M$29.62M-29.37570News CoverageAnalyst UpgradeGap DownTPSTTempest Therapeutics2.4663 of 5 stars$10.85-1.3%$30.00+176.5%-47.4%$48.80MN/A-0.7420VRCAVerrica Pharmaceuticals4.077 of 5 stars$5.06-1.0%$80.00+1,481.0%-74.9%$48.22M$7.57M-0.6140Positive NewsLTRNLantern Pharma2.3665 of 5 stars$4.06-5.8%$25.00+515.8%-5.2%$46.54MN/A-2.2820PEPGPepGen2.8355 of 5 stars$1.49+6.4%$7.67+414.5%-83.2%$45.92MN/A-0.5030NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3398 of 5 stars$1.14-8.1%$7.50+557.9%+12.8%$45.44M$40K-3.006Negative NewsShort Interest ↑ATHEAlterity Therapeutics2.4835 of 5 stars$5.17+2.0%$12.00+132.1%+268.3%$44.96MN/A0.0010News CoverageHigh Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+10.6%$44.95M$25.07M-0.8040ANVSAnnovis Bio2.1229 of 5 stars$2.34+2.1%$17.33+641.4%-69.9%$44.62MN/A-1.153 Related Companies and Tools Related Companies FibroGen Competitors Tempest Therapeutics Competitors Verrica Pharmaceuticals Competitors Lantern Pharma Competitors PepGen Competitors Nabriva Therapeutics Competitors RenovoRx Competitors Alterity Therapeutics Competitors Aadi Bioscience Competitors Annovis Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNGX Stock Alerts